Pancreatic Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Pancreatic Cancer, including details on symptoms, causes, treatment, information.

Volume 2 (2005), Issue 5 (May)

1. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification.
   Oncology, 68(1): 79-86. [Abstract] [Full-text]
2. Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas.
   Am J Surg, 189(5): 632-6; discussion 637. [Abstract] [Full-text]
3. Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results.
   Br J Surg, 92(5): 547-56. [Abstract] [Full-text]
4. Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells.
   Cancer Res, 65(9): 3877-82. [Abstract] [Full-text]
5. Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors.
   Cancer Res, 65(9): 3664-70. [Abstract] [Full-text]
6. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia.
   Clin Cancer Res, 11(9): 3587-96. [Abstract] [Full-text]
7. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases.
   Clin Cancer Res, 11(9): 3233-42. [Abstract] [Full-text]
8. A high peripheral microvessel density count correlates with a poor prognosis in pancreatic cancer.
   J Gastroenterol, 40(4): 402-8. [Abstract] [Full-text]
9. Noninvasive measurement of viable cell number in tissue-engineered constructs in vitro, using 1H nuclear magnetic resonance spectroscopy.
   Tissue Eng, 11(3): 404-14. [Abstract] [Full-text]
10. 3,5,3'-Triiodo-L-thyronine enhances the differentiation of a human pancreatic duct cell line (hPANC-1) towards a beta-cell-Like phenotype.
    J Cell Physiol, 204(1): 286-96. [Abstract] [Full-text]
11. Pigmented solid-pseudopapillary neoplasm of the pancreas.
    Pathol Int, 55(5): 280-4. [Abstract] [Full-text]
12. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
    Cancer Chemother Pharmacol, 56(1): 46-54. [Abstract] [Full-text]
13. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer.
    J Hum Genet, 50(4): 159-67. [Abstract] [Full-text]
14. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.
    Eur J Endocrinol, 152(5): 757-67. [Abstract] [Full-text]
15. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy.
    J Gene Med, 7(5): 672-80. [Abstract] [Full-text]
16. Spontaneous regression of a pancreatic head mass and biliary obstruction due to autoimmune pancreatitis.
    Pancreatology, 5(2): 300-3. [Abstract] [Full-text]
17. Successful treatment of solid-pseudopapillary tumor of the pancreas with multiple liver metastases.
    Pancreatology, 5(2): 289-94. [Abstract] [Full-text]
18. Total dorsal pancreatectomy for intraductal papillary mucinous neoplasm in a patient with pancreas divisum.
    Pancreatology, 5(2): 285-8. [Abstract] [Full-text]
19. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI.
    Pancreatology, 5(2): 266-72. [Abstract] [Full-text]
20. Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer.
    Pancreatology, 5(2): 259-65. [Abstract] [Full-text]
21. Inhibition of different intracellular signal cascades in human pancreatic cancer cells.
    Pancreatology, 5(2): 251-8. [Abstract] [Full-text]
22. Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance.
    Pancreatology, 5(2): 229-33. [Abstract] [Full-text]
23. Defective DNA mismatch repair in long-term (> or =3 years) survivors with pancreatic cancer.
    Pancreatology, 5(2): 220-7; discussion 227-8. [Abstract] [Full-text]
24. Somatostatin-producing pancreatic endocrine carcinoma presented as relapsing cholangitis -- a case report.
    Pancreatology, 5(2): 295-9. [Abstract] [Full-text]
25. Osteoclast-like giant cell tumor of the pancreas associated with mucus-secreting adenocarcinoma. Case report and discussion of the histogenesis.
    Pancreatology, 5(2): 279-84. [Abstract] [Full-text]
26. 'Understanding the development of pancreatic cancer will emerge from basic research'. An interview with Prof. Hans G. Beger. Interviewed by Martin E. Fernandez-Zapico.
    Pancreatology, 5(2): 116-8. [Abstract] [Full-text]
27. Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy.
    Dig Surg, 22(1): 80-5. [Abstract] [Full-text]
28. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer.
    Dig Surg, 22(1): 55-61; discussion 62. [Abstract] [Full-text]
29. Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas.
    Dig Liver Dis, 37(3): 190-4. [Abstract] [Full-text]
30. Molecular targeting of pancreatic disorders.
    World J Surg, 29(3): 325-33. [Abstract] [Full-text]
31. Somatostatin, somatostatin receptors, and pancreatic cancer.
    World J Surg, 29(3): 293-6. [Abstract] [Full-text]
32. Role of proteases in pancreatic carcinoma.
    World J Surg, 29(3): 258-63. [Abstract] [Full-text]
33. Intravenous delivery of liposome-mediated nonviral DNA is less toxic than intraperitoneal delivery in mice.
    World J Surg, 29(3): 339-43. [Abstract] [Full-text]
34. Tissue MicroArray analyses of pancreatic duodenal homeobox-1 in human cancers.
    World J Surg, 29(3): 334-8. [Abstract] [Full-text]
35. Abrogation of transforming growth factor-beta signaling in pancreatic cancer.
    World J Surg, 29(3): 312-6. [Abstract] [Full-text]
36. Smoking-gene interaction and disease development: relevance to pancreatic cancer and atherosclerosis.
    World J Surg, 29(3): 344-53. [Abstract] [Full-text]
37. Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications.
    World J Surg, 29(3): 297-305. [Abstract] [Full-text]
38. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.
    Cancer Cell, 7(5): 469-83. [Abstract] [Full-text]
39. Chromosomal instability in mouse metastatic pancreatic cancer--it's Kras and Tp53 after all.
    Cancer Cell, 7(5): 405-7. [Abstract] [Full-text]
40. Fine-needle aspiration of ganglioneuroma.
    Diagn Cytopathol, 32(6): 363-6. [Abstract] [Full-text]
41. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment.
    Clin Cancer Res, 11(10): 3790-8. [Abstract] [Full-text]
42. Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells.
    Biochem Biophys Res Commun, 332(1): 89-94. [Abstract] [Full-text]
43. Decrease in glucose-stimulated insulin secretion following exposure to magnetic fields.
    Biochem Biophys Res Commun, 332(1): 28-32. [Abstract] [Full-text]
44. Duodenal diverticulum mimicking a cystic pancreatic neoplasm.
    Br J Radiol, 78(930): 562-4. [Abstract] [Full-text]
45. BRCA2 regulates homologous recombination in response to DNA damage: implications for genome stability and carcinogenesis.
    Cancer Res, 65(10): 4117-25. [Abstract] [Full-text]
46. Pancreatic cancer--is an aggressive approach justified?
    Ann R Coll Surg Engl, 87(3): 163-6. [Abstract] [Full-text]
47. Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
    Cancer Sci, 96(5): 295-302. [Abstract] [Full-text]
48. Effect of PK11195, a peripheral benzodiazepine receptor agonist, on insulinoma cell death and insulin secretion.
    Apoptosis, 10(3): 537-44. [Abstract] [Full-text]
49. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
    J Clin Oncol, 23(15): 3509-16. [Abstract] [Full-text]
50. Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma.
    Mod Pathol, 18(6): 779-87. [Abstract] [Full-text]
51. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways.
    Mod Pathol, 18(6): 752-61. [Abstract] [Full-text]
52. Hand-assisted laparoscopic pylorus-preserving pancreaticoduodenectomy for pancreas head disease.
    Am J Surg, 189(6): 734-7. [Abstract] [Full-text]
53. In vitro effects of keyhole limpet hemocyanin in breast and pancreatic cancer in regards to cell growth, cytokine production, and apoptosis.
    Am J Surg, 189(6): 680-4. [Abstract] [Full-text]
54. TIMP-1 antisense gene transfection attenuates the invasive potential of pancreatic cancer cells in vitro and inhibits tumor growth in vivo.
    Am J Surg, 189(6): 675-9. [Abstract] [Full-text]
55. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas.
    Histopathology, 46(6): 668-76. [Abstract] [Full-text]
56. All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells.
    Cancer Lett, 224(2): 303-10. [Abstract] [Full-text]
57. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
    Neuroendocrinology, 81(1): 1-9. [Abstract] [Full-text]
58. Endoscopic perductal electrolytic ablation of the pancreas: experimental studies of morbidity and mortality.
    Dig Dis, 23(1): 83-91. [Abstract] [Full-text]
59. Inositol hexaphosphate (IP6): a novel treatment for pancreatic cancer.
    J Surg Res, 126(2): 199-203. [Abstract] [Full-text]
60. Laminin gamma2-chain fragment circulating level increases in patients with metastatic pancreatic ductal cell adenocarcinomas.
    Cancer Lett, 225(1): 167-76. [Abstract] [Full-text]
61. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8.
    Int J Cancer, 116(2): 275-81. [Abstract] [Full-text]
62. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
    Lancet Oncol, 6(6): 369-76. [Abstract] [Full-text]

© 2004-2008 Pancreatic Cancer Research Today. All Rights Reserved.